On-Demand Webinar: Cytometry for High-Throughput Screening to Advance the Immunotherapeutic Space
Overview
Immunotherapy represents an innovation in the treatment of disease, marking a fundamental change in our approach to treating a range of conditions, particularly cancer. This therapeutic strategy harnesses and amplifies the innate power of the immune system, assisting it to recognize and combat, malignant cells and pathogens more effectively.
By leveraging the body's own defense mechanisms, immunotherapy offers a personalized, and often less invasive, alternative to traditional treatments such as radiation and chemotherapy. As research progresses, the potential of immunotherapy continues to reveal insights, indicating a future where the body's own resilience becomes the cornerstone of curing and managing disease.
Crucial to the success of this approach is the use of advanced diagnostic tools, among which flow cytometry is pivotal. This technology is instrumental to both the design and monitoring of immunotherapies, through cell profiling, functional assay and drug screening. Thus providing insights which guide personalized treatment plans. However, traditional flow cytometry can be slow.
Introducing high-throughput screening (HTS) by cytometry, which enables the rapid analysis of a large number of cells, allowing for the identification and characterization of cellular responses.
In this webinar, we delve into the critical role of high-throughput screening (HTS) by cytometry, in the research and development of immunotherapies. The value of HTS to researchers is highlighted.
Complete the Form to Access the Webinar
The webinar panel also discusses:
- How immunotherapy is personalized for individual patients. The challenges in customizing treatments for diverse patient populations.
- How patient response to immunotherapy is monitored over time.
- Details of how high-throughput screening (HTS) cytometry identifies cellular responses, and contributes to the development and monitoring of immunotherapies.
- The advancements necessary to propel immunotherapies forward.
Webinar Speakers
Kevin Chen, MSc
Translation Scientist
Arcellx
Kevin Z. Chen holds a Master of Science in Cancer Biology from Emory University. As a Scientist in the Translational Sciences Department - Biomarkers and Bioanalysis Group at Arcellx, he specializes in utilizing spectral and conventional flow cytometry platforms to evaluate clinical biomarkers of patient response both pre- and post-CAR-T infusion.
Kevin leads the development and validation of multiparameter flow cytometry assays, employing over 25 fluorochromes to comprehensively characterize T cell phenotype and function. He also serves as a device manager for laser cytometers. Kevin's research has contributed to the understanding of T cell immunotherapy, particularly in enhancing CAR-T cell manufacturing processes.
Raffaello Cimbro
Global Leader of Flow Cytometry
AstraZeneca
As the Director of Flow Cytometry at AstraZeneca, I lead a global team operating in Washington DC, Cambridge and Boston. We support the work of over 600 scientists and 150 projects each year, supporting the discovery and development of new therapies for various diseases.
With an education in biotechnology and over 15 years of experience in flow cytometry, immunology, virology, and data science, I have a strong background in both human and non-human primate animal models, neuroscience, and cell therapy.
Jonah Riddell, PhD
Product Manager
Sartorius
Jonah Riddell, PhD is a Product Manager supporting the iQue® HTS by Cytometry Platform at Sartorius Corporation. He is both an accomplished benchtop scientist and commercial leader in immunology with over 25 years of experience. Integrating a deep understanding of immunology with strategic market planning and cross-functional team leadership he is looking to innovate new products to aid in clinical and pre-clinical research.
Jonah has been associated with esteemed institutions such as the Harvard Stem Cell Institute, Boston Children's Hospital, Roswell Park Cancer Institute, Cell Signaling Technology, Advanced Instruments, Bio-Techne where his experience spans from academic to biopharma to clinical testing.
